Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
PRNewswire - November 13, 2006
"Inclusion in the CDC's guidelines reinforces the importance of Tindamax(R) in treating a very common sexually transmitted disease," said Neill Walsdorf, Jr., president of Mission Pharmacal. "Because Tindamax(R) has been shown to be better tolerated than metronidazole, patients and physicians alike will benefit from having this new option for first line treatment of trichomoniasis." Tindamax(R) as a single 2g dose is also recommended by the CDC for patients having failed treatment with single dose metronidazole.
Because trich is generally asymptomatic or only mildly symptomatic, trich- infected individuals are often in the dark about their infection. Moreover, research indicates that many healthcare professionals are under-utilizing newer point-of-care methods that more rapidly and accurately diagnose trich. Untreated, trichomoniasis can lead to both an increased risk of infertility and enhanced transmission of HIV in men and women, as well as increased risk for cervical cancer and pelvic inflammatory disease in women.
"As the most prevalent curable STD in the United States, the timely diagnosis and treatment of trichomoniasis is imperative to reducing other more serious conditions. Healthcare providers need to be vigilant about testing their patients who are sexually active for trich because they may not experience any symptoms," stated Dr. Jane Schwebke, professor of infectious diseases at the University of Alabama at Birmingham. "Fortunately, trichomoniasis can be cured with single dose therapy in both women and men."
The Sexually Transmitted Diseases Guidelines are published to assist healthcare providers in their efforts to prevent, diagnose and treat STDs. They were developed by the CDC after consultation with a group of professionals knowledgeable in the field of STDs, and serve as an update to the guidelines issued in 2002. The full report can be accessed at http://www.cdc.gov/std/treatment/default.htm.
About Trichomoniasis
Trichomoniasis, which is caused by the single-celled parasite Trichomonas vaginalis, is the most common curable sexually transmitted disease (STD) in the United States. There are an estimated 7.4 million cases of trich each year in the U.S.
Trich is often asymptomatic or only mildly symptomatic. Signs and symptoms of trichomoniasis in women include itching, redness and a yellow, green or grey vaginal discharge that may be frothy or sticky and have a foul odor. Urination and intercourse may be painful, and the symptoms may worsen during menstruation. When symptoms are present in men, they may consist of urethral discharge and irritation.
When left untreated, trichomoniasis may enhance both the acquisition and transmission of HIV. The genital inflammation caused by trichomoniasis can increase a woman's susceptibility to HIV infection if she is exposed to the virus. Trich also has been shown to increase the risk of infertility in women and may play a role in promoting cervical cancer and pelvic inflammatory disease. In a large Finnish study, trich was associated with a six-fold increased risk of cervical cancer in women compared with those who were uninfected. The STD has also been linked to preterm birth and postoperative infection in women, and lower sperm motility and nongonococcal urethritis in men.
Sexual partners should be treated simultaneously for maximum efficacy and prevention of re-infection. More information on trich is available at http://www.trichomoniasis.net.
About Tindamax(R)
Tindamax(R), a second-generation 5-nitroimidazole compound, is indicated in the United States for the treatment of trichomoniasis, the intestinal infections giardiasis and intestinal amebiasis, and amebic liver abscess. It has been approved for use in the United States since May 2004 and is recommended as one of the drugs of choice for the treatment of trichomoniasis by the Centers for Disease Control and Prevention.
Full prescribing information for Tindamax(R), as well as information about trichomoniasis, is available at http://www.tindamax.com.
About Mission Pharmacal
Mission Pharmacal, the maker of Citracal(R), is a family-owned pharmaceutical company based in San Antonio, TX. For more than 50 years, the company has been dedicated to identifying unmet health needs in the marketplace and developing innovative prescription and over-the-counter products to meet them. Currently, Mission Pharmacal provides physicians and consumers with pharmaceutical, nutritional and diagnostic products. For more information, visit http://www.missionpharmacal.com.
SOURCE Mission Pharmacal
http://www.missionpharmacal.com
http://www.tindamax.com
http://www.trichomoniasis.net
http://www.cdc.gov/std/treatment/default.htm/
061113
PR061114
Copyright © 2006 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .